# Clinical Trials Data EGFR - Document 61

# Characterization of Circulating Tumor Cells (CTC-s) in Patients With Locally Advanced or Metastatic Stage IV Breast Cancer

## Clinical Trial: https://clinicaltrials.gov/study/NCT01048918

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Patients must be \\> 18 years old.\n\* Patients are being treated for breast cancer at City of Hope (COH).",  
 "healthyVolunteers": false,  
 "sex": "FEMALE",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Brawerman Center-Outpatient clinics (City of Hope), Pasadena Satellite Office",

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
This trial information \*\*does not mention EGFR mutations\*\*, either as an inclusion or exclusion criteria. Therefore, based on the provided information alone, we \*\*cannot determine\*\* if a patient with an EGFR mutation would be eligible. The criteria only specify age, breast cancer treatment at City of Hope, and female sex. The presence or absence of an EGFR mutation is not addressed.